Flynpovi™ (CPP-1X/sulindac)
Familial Adenomatous Polyposis (FAP)
Key Facts
About Panbela Therapeutics
Panbela Therapeutics is a clinical-stage biotech focused on developing novel polyamine analog therapeutics for oncology, with a lead program in pancreatic cancer. The company's core achievement is advancing ivospemin (SBP-101) into a global Phase 3 trial (ASPIRE) for metastatic pancreatic ductal adenocarcinoma, following promising Phase 1b data. Its strategy centers on a capital-efficient, virtual model, targeting high-mortality cancers where polyamine pathway dysregulation is a key driver. Panbela aims to establish a new treatment paradigm by disrupting a fundamental metabolic pathway common across many aggressive tumors.
View full company profileAbout Panbela Therapeutics
Panbela Therapeutics is a clinical-stage biotech focused on developing novel polyamine analog therapeutics for oncology, with a lead program in pancreatic cancer. The company's core achievement is advancing ivospemin (SBP-101) into a global Phase 3 trial (ASPIRE) for metastatic pancreatic ductal adenocarcinoma, following promising Phase 1b data. Its strategy centers on a capital-efficient, virtual model, targeting high-mortality cancers where polyamine pathway dysregulation is a key driver. Panbela aims to establish a new treatment paradigm by disrupting a fundamental metabolic pathway common across many aggressive tumors.
View full company profileTherapeutic Areas
Other Familial Adenomatous Polyposis (FAP) Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Phase 3 |
| Global Early Access Program for eRapa (with Biodexa) | Tanner Pharma Group | N/A (Early Access Program) |